Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants
Open Access
- 18 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 6 (1) , 59-74
Abstract
Background: As SARS-CoV-2 continues to mutate into Variants of Concern (VOC), there is growing and urgent need to develop effective antivirals to combat COVID-19. Monoclonal antibodies developed earlier are no longer capable of effectively neutralizing currently active VOCs. This report describes the design of variant-agnostic chimeric molecules consisting of an Angiotensin-Converting Enzyme 2 (ACE-2) domain mutated to retain ultrahigh affinity binding to a wide variety of SARS-CoV-2 variants, coupled to an Fc-silent immunoglobulin domain that eliminates antibody-dependent enhancement and extends biological half-life. Methods: Molecular modeling, Surrogate Viral Neutralization tests (sVNTs) and infection studies of human airway organoid cultures were performed with synthetic chimeras, SARS-CoV-2 spike protein mimics and SARS-CoV-2 Omicron variants B.1.1.214, BA.1, BA.2 and BA.5. Results: ACE-2 mutations L27, V34 and E90 resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 93 pM and 73 pM for binding to the Alpha B1.1.7 and Omicron B.1.1.529 variants, and notably, 78fM, 133fM and 1.81pM affinities to the Omicron BA.2, BA2.75 and BQ.1.1 subvariants, respectively. sVNT assays revealed titers of ≥4.9 ng/ml, for neutralization of recombinant viral proteins corresponding to the Alpha, Delta and Omicron variants. The values above were obtained with LVE-ACE-2/mAB chimeras containing the FcRn-binding Y-T-E sequence which extends biological half-life 3–4-fold. Conclusions: The ACE-2-mutant/Fc silent fusion proteins described have ultrahigh affinity to a wide variety of SARS-CoV-2 variants including Omicron. It is proposed that these chimeric ACE-2/mABs will constitute variant-agnostic and cost-effective prophylactics against SARS-CoV-2, particularly when administered nasally.Keywords
All Related Versions
Funding Information
- Paradigm Immunotherapeutics Inc
This publication has 34 references indexed in Scilit:
- Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?Pharmaceutics, 2018
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsScience Translational Medicine, 2017
- An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved StabilityJournal of Pharmaceutical Sciences, 2017
- Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc ReceptorJournal of Biological Chemistry, 2016
- TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike ProteinJournal of Virology, 2014
- A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2013
- A Novel Side-Chain Orientation Dependent Potential Derived from Random-Walk Reference State for Protein Fold Selection and Structure PredictionPLOS ONE, 2010
- Ab Initio Protein Structure Prediction Using Chunk-TASSERBiophysical Journal, 2007
- Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological ConsequencesThe Journal of Immunology, 2002
- Distance‐scaled, finite ideal‐gas reference state improves structure‐derived potentials of mean force for structure selection and stability predictionProtein Science, 2002